EphB4
EphB4 Molekülinformation
| Englischer Name | Ephrin type-B receptor 4 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 2 | Target-Alias | Ephrin type-B receptor 4，MYK1，EPHB4，HTK，EPH Receptor B4，Tyrosine-Protein Kinase TYRO11，TYRO11，Tyrosine-Protein Kinase Receptor HTK，Soluble EPHB4 Variant 2，Soluble EPHB4 Variant 3，Ephrin Receptor EphB4，EC 2.7.10.1，HFASD，LMPHM7，CMAVM2，EC 2.7.10，EC:2.7.10.1，Soluble EPHB4 Variant 1，Receptor， EphB4，Hepatoma transmembrane kinase |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical | ||
| Englischer Name | Ephrin type-B receptor 4 |
| Target-Alias | Ephrin type-B receptor 4，MYK1，EPHB4，HTK，EPH Receptor B4，Tyrosine-Protein Kinase TYRO11，TYRO11，Tyrosine-Protein Kinase Receptor HTK，Soluble EPHB4 Variant 2，Soluble EPHB4 Variant 3，Ephrin Receptor EphB4，EC 2.7.10.1，HFASD，LMPHM7，CMAVM2，EC 2.7.10，EC:2.7.10.1，Soluble EPHB4 Variant 1，Receptor， EphB4，Hepatoma transmembrane kinase |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 2 |
| Höchste Forschungs- und Entwicklungsphase | Phase 3 Clinical |
EphB4 Produktliste
- Attribut
Protein (2)
- Produktbibliothek
Online (2)
- Spezies
Human (2)
- Etikett
His Tag (2)
- Marker
Unconjugated (1)Biotin-labeled (1)
| Produktnummer | Spezies | Expressionssystem | Produktbeschreibung | Proteinstruktur | Reinheit | Eigenschaften | Vorbestellen/Bestellen |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human EphB4 Protein, His Tag |  |  |  In den Warenkorb legen | ||
| Human | HEK293 | Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling) |  | | In den Warenkorb legen |
Gesamtmenge2
- 1
EphB4 Molekülhintergrund
Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.
EphB4 Molekülalias
EphB4,HTK,MYK1,TYRO11
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| sEphB4-HSA | Vas-01; sEphB4-HSA | Phase 3 Clinical | Vasgene | Bile Duct Neoplasms; Bone metastases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gallbladder Neoplasms; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic-Myeloproliferative Diseases; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| Tesevatinib | XL-647; KD-020; KD-019; EXEL-7647 | Phase 2 Clinical | Exelixis Inc | Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive | Details |
- Molekülinformation
- Produktliste
- Klinische Arzneimittelinformation